Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition
Gilda Varricchi, Stefania Loffredo, Giancarlo Marone, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 16, pp. 3934-3934
Open Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment
Zhenyu Xie, Xin Li, Yuzhen He, et al.
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 84
A new risk factor indicator for papillary thyroid cancer based on immune infiltration
Yang Zhou, Xiyi Wei, Yitong Pan, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 82
New insight in endocrine-related adverse events associated to immune checkpoint blockade
Giusy Elia, Silvia Martina Ferrari, Maria Rosaria Galdiero, et al.
Best Practice & Research Clinical Endocrinology & Metabolism (2019) Vol. 34, Iss. 1, pp. 101370-101370
Open Access | Times Cited: 81
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Remo Poto, Teresa Troiani, Gjada Criscuolo, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 68
Emerging Biomarkers in Thyroid Practice and Research
Shipra Agarwal, Andrey Bychkov, Chan Kwon Jung
Cancers (2021) Vol. 14, Iss. 1, pp. 204-204
Open Access | Times Cited: 60
Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors
Peitao Zhang, Haixia Guan, Shukai Yuan, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 55
Differentiated thyroid carcinoma: An update
Pepijn van Houten, Romana T. Netea‐Maier, Johannes W. A. Smit
Best Practice & Research Clinical Endocrinology & Metabolism (2022) Vol. 37, Iss. 1, pp. 101687-101687
Open Access | Times Cited: 45
Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities
Lizhuo Zhang, Qingqing Feng, Jiafeng Wang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 4, pp. 188928-188928
Open Access | Times Cited: 33
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study
Do‐Youn Oh, Alain P. Algazi, Jaume Capdevila, et al.
Cancer (2023) Vol. 129, Iss. 8, pp. 1195-1204
Open Access | Times Cited: 25
Dynamic Cancer Cell Heterogeneity: Diagnostic and Therapeutic Implications
Valérie Jacquemin, Mathieu Antoine, Geert Dom, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 280-280
Open Access | Times Cited: 33
The emerging role of T follicular helper (TFH) cells in aging: Influence on the immune frailty
Gilda Varricchi, Leonardo Bencivenga, Remo Poto, et al.
Ageing Research Reviews (2020) Vol. 61, pp. 101071-101071
Closed Access | Times Cited: 45
Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors
Joana Lima Ferreira, Cláudia Costa, Bernardo Marques, et al.
Cancer Immunology Immunotherapy (2020) Vol. 70, Iss. 2, pp. 299-309
Closed Access | Times Cited: 44
Thyroid-related adverse events induced by immune checkpoint inhibitors
Alexandra Chera, Andreea Lucia Stancu, Octavian Bucur
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 27
Immune Microenvironment of Thyroid Cancer
Hongyu Yin, Yemei Tang, Yujia Guo, et al.
Journal of Cancer (2020) Vol. 11, Iss. 16, pp. 4884-4896
Open Access | Times Cited: 36
Cancer Stem Cells in Thyroid Tumors: From the Origin to Metastasis
Veronica Veschi, Francesco Verona, Melania Lo Iacono, et al.
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 35
Advances and challenges in thyroid cancer: The interplay of genetic modulators, targeted therapies, and AI-driven approaches
Srinjan Bhattacharya, Rahul Kumar Mahato, Satwinder Singh, et al.
Life Sciences (2023) Vol. 332, pp. 122110-122110
Open Access | Times Cited: 12
Tumor-associated macrophages as a potential therapeutic target in thyroid cancers
Liya Zhu, Xiu Juan Li, Prakash Gangadaran, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 12, pp. 3895-3917
Open Access | Times Cited: 11
The role of immune cells and immune related genes in the tumor microenvironment of papillary thyroid cancer and their significance for immunotherapy
Xumei Li, Jie Jian, Anzhi Zhang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Causal role of immune cells in thyroid cancer: a two-sample Mendelian randomization study
Shurong Wang, Zhouyu Fang, Wenjin Xiao, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Identification of hub genes in papillary thyroid carcinoma: robust rank aggregation and weighted gene co-expression network analysis
Yang Liu, Ting‐Yu Chen, Zhi-Yan Yang, et al.
Journal of Translational Medicine (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 29
Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition
Jingtai Zhi, Peitao Zhang, Wei Zhang, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 106, Iss. 1, pp. 91-107
Open Access | Times Cited: 26
Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs
Alessandro Prete, Antonio Matrone, Carla Gambale, et al.
Cancers (2021) Vol. 13, Iss. 13, pp. 3200-3200
Open Access | Times Cited: 23
Immune profiling identifies CD8+ T-cell subset signatures as prognostic markers for recurrence in papillary thyroid cancer
Zhen Chen, Mengli Guo, Ya-yi Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 15
Differentiated Thyroid Cancer, From Active Surveillance to Advanced Therapy: Toward a Personalized Medicine
Antonio Matrone, Maria Cristina Campopiano, Alice Nervo, et al.
Frontiers in Endocrinology (2020) Vol. 10
Open Access | Times Cited: 22
EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer
Guoliang Wang, Lejian He, Shengcai Wang, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 8, pp. e2970-e2981
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top